Sofinnova Partners is a life sciences venture capital firm founded in 1972, managing over €4 billion in assets across seven investment strategies. The firm operates from Paris, Milan, and London, backing early-stage to growth-stage companies in biopharma, medtech, digital medicine, industrial biotech, and agriculture. Sofinnova Partners has backed more than 500 companies over 50 years, building market leaders globally. The firm is known as a company creator, investing as founding or lead investor and working hands-on with entrepreneurs. Its strategies include Sofinnova Capital (early-stage biopharma and medtech), Sofinnova MD Start (in-house medtech accelerator), Sofinnova Crossover (growth-stage biotech and medtech preparing for commercialization), Sofinnova Industrial Biotech (sustainable agriculture and materials), Sofinnova Telethon (early-stage Italian rare genetic disease companies), Sofinnova Digital Medicine (techbio and healthtech at the intersection of biology, data, and computation), and Sofinnova Biovelocita (European biotech accelerator partnering with research organizations). Recent portfolio activity includes Series B financing for Mironid (rare kidney disease), partnerships by Mediar Therapeutics, HAYA Therapeutics, Moon Surgical, and MaxCyte, and Mission Therapeutics' asset licensing deals.
Profile auto-generated from public sources — details unverified.
Antoine Papiernik
Chairman Managing Partner
Henrijette Richter
Managing Partner
Graziano Seghezzi
Managing Partner
Joe Anderson
Partner, Crossover Strategy
Guillaume Baxter
Partner, Industrial Biotech Strategy
Maina Bhaman
Partner, Capital Strategy
Gabriella Camboni
Partner, Biovelocita Strategy
Matthieu Coutet
Partner, Biovelocita Strategy
Cécile Dupont
Partner, MD Start Strategy
David Evans
Partner